These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 36037651)

  • 1. Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8
    Cheng CC; Ho AS; Peng CL; Chang J; Sie ZL; Wang CL; Chen YL; Chen CY
    Int Immunopharmacol; 2022 Nov; 112():109110. PubMed ID: 36037651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irradiation Suppresses IFNγ-Mediated PD-L1 and MCL1 Expression in EGFR-Positive Lung Cancer to Augment CD8
    Wang CI; Chang YF; Sie ZL; Ho AS; Chang JS; Peng CL; Cheng CC
    Cells; 2021 Sep; 10(10):. PubMed ID: 34685495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiotherapy enhances CXCR3
    Wang CL; Ho AS; Chang CC; Sie ZL; Peng CL; Chang J; Cheng CC
    Cancer Immunol Immunother; 2023 Jun; 72(6):1865-1880. PubMed ID: 36688994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-intrinsic IFNα and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment.
    Cheng CC; Chang J; Ho AS; Sie ZL; Peng CL; Wang CL; Dev K; Chang CC
    Cancer Immunol Immunother; 2024 Jul; 73(9):175. PubMed ID: 38953994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SRSF10 facilitates HCC growth and metastasis by suppressing CD8
    Luo X; Zhang Z; Li S; Wang Y; Sun M; Hu D; Jiang J; Wang Y; Ji X; Chen X; Zhang B; Liang H; Li Y; Liu B; Xu X; Wang S; Xu S; Nie Y; Wu K; Fan D; Liu D; Huang W; Xia L
    Int Immunopharmacol; 2024 Jan; 127():111376. PubMed ID: 38113691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paeoniflorin inhibits hepatocellular carcinoma growth by reducing PD-L1 expression.
    Gao M; Zhang D; Jiang C; Jin Q; Zhang J
    Biomed Pharmacother; 2023 Oct; 166():115317. PubMed ID: 37597322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of PD-1 blockade with interferon-α has a synergistic effect on hepatocellular carcinoma.
    Zhu Y; Chen M; Xu D; Li TE; Zhang Z; Li JH; Wang XY; Yang X; Lu L; Jia HL; Dong QZ; Qin LX
    Cell Mol Immunol; 2022 Jun; 19(6):726-737. PubMed ID: 35459855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs.
    Li Z; Bu J; Zhu X; Zhou H; Ren K; Chu PK; Li L; Hu X; Ding X
    Biomater Adv; 2022 May; 136():212761. PubMed ID: 35929305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
    Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
    Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
    Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
    Liu J; Liu Y; Meng L; Liu K; Ji B
    Oncol Rep; 2017 Aug; 38(2):899-907. PubMed ID: 28627705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.
    Liao J; Zeng DN; Li JZ; Hua QM; Xiao Z; He C; Mao K; Zhu LY; Chu Y; Wen WP; Zheng L; Wu Y
    Hepatol Int; 2020 Jan; 14(1):80-95. PubMed ID: 31802389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma cells.
    Cho S; Kim W; Yoo D; Han Y; Hwang H; Kim S; Kim J; Park S; Park Y; Jo H; Pyun JC; Lee M
    Sci Rep; 2024 Jan; 14(1):1751. PubMed ID: 38243049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
    Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
    J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LAIR1-mediated resistance of hepatocellular carcinoma cells to T cells through a GSK-3β/β-catenin/MYC/PD-L1 pathway.
    Pan B; Ke X; Qiu J; Ye D; Zhang Z; Zhang X; Luo Y; Yao Y; Wu X; Wang X; Tang N
    Cell Signal; 2024 Mar; 115():111039. PubMed ID: 38199599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma.
    Gao ZX; Zhang ZS; Qin J; Zhang MZ; Cao JL; Li YY; Wang MQ; Hou LL; Fang D; Xie SQ
    Phytomedicine; 2023 Apr; 112():154715. PubMed ID: 36821999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma.
    Huang CY; Wang Y; Luo GY; Han F; Li YQ; Zhou ZG; Xu GL
    J Immunother; 2017; 40(9):323-333. PubMed ID: 29028787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.